To evaluate the dermatological safety of hair oil and shampoo on women with sensitive scalp conditions.

A single arm, single centered clinical study on healthy human subjects, to evaluate the suitability of the product regime on sensitive scalp.

Status

Active, not recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2018/01/011454

Enrollment

Registered

2018-01-19

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Intervention1: VBB01: Vatika B&B Shampoo containing Aqua, Cocoamidopropyl Betaine, Sodium Lauroyl Sarcosinate, PEG-80 Sorbitan Laurate, Glycerine, PEG-4 Rapeseedamide, PEG-150 Distearate, Parfum, Niac

Eligibility

Inclusion criteria

Inclusion criteria: 1) Volunteer in generally in good health. 2) Volunteer with sensitive scalp condition. 3) Healthy female volunteer between 19 to 35 years of age (both inclusive) 4) Volunteer willing to give a written informed consent and come for regular observation. 5) The volunteer has not participated in a similar clinical investigation in the same past four weeks.

Exclusion criteria

Exclusion criteria: 1) A known history or present condition of an allergic response to any cosmetic products. 2) Skin disease (e.g. psoriasis, atopic dermatitis or other cutaneous manifestations on the scalp), which would interfere with the test readings. 3) Medications (e.g. Steroids or antihistamines), which would compromise the study. 4) Pregnant or lactating. 5) Volunteer viewed by the investigator as not being able to complete the study or participating in another study.

Design outcomes

Primary

Measure	Time frame
To evaluate the safety of the Product Regimen (shampoo & oil) on healthy human female subjects with sensitive scalp condition.Timepoint: Screening, week 0, week 2 and week 4.	—

Secondary

Measure	Time frame
To evaluate overall safety of the subject throughout the study.Timepoint: Screening, week 0, week 2 and week 4.	—

Countries

India

Contacts

Public ContactManmohan Sharma

Dabur India Limited

manmohan.sharma@dabur.com0120-3378591

Outcome results